

# Jochen K Lennerz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8346532/publications.pdf>

Version: 2024-02-01

140  
papers

8,496  
citations

71061

41  
h-index

49868

87  
g-index

144  
all docs

144  
docs citations

144  
times ranked

14226  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. <i>Seminars in Cancer Biology</i> , 2022, 84, 129-143.	4.3	41
2	t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. <i>Blood Advances</i> , 2022, 6, 818-827.	2.5	5
3	Immune cell profiles in the tumor microenvironment of early-onset, intermediate-onset, and later-onset colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 933-942.	2.0	18
4	Next-generation sequencing in the evaluation of biliary strictures in patients with primary sclerosing cholangitis. <i>Cancer Cytopathology</i> , 2022, 130, 215-230.	1.4	11
5	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 719-727.	3.2	46
6	Abstract P3-09-11: Clinical characteristics associated with <i>BRCA1/2</i> mutations identified on routine tumor tissue genotyping in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-11-P3-09-11.	0.4	0
7	Human and mouse trigeminal ganglia cell atlas implicates multiple cell types in migraine. <i>Neuron</i> , 2022, 110, 1806-1821.e8.	3.8	61
8	Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4322.	1.8	7
9	Development of oil-based gels as versatile drug delivery systems for pediatric applications. <i>Science Advances</i> , 2022, 8, .	4.7	19
10	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024.	0.8	0
11	Abstract 5248: CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR+ MBC) with <i>ESR1</i> mutations and fusions. <i>Cancer Research</i> , 2022, 82, 5248-5248.	0.4	0
12	Abstract 4100: Developmental deconvolution for classification of cancer origin. <i>Cancer Research</i> , 2022, 82, 4100-4100.	0.4	0
13	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
14	Presymptomatic Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Among Residents and Staff at a Skilled Nursing Facility: Results of Real-time Polymerase Chain Reaction and Serologic Testing. <i>Clinical Infectious Diseases</i> , 2021, 72, 686-689.	2.9	34
15	COVID-19-neutralizing antibodies predict disease severity and survival. <i>Cell</i> , 2021, 184, 476-488.e11.	13.5	586
16	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 123-132.	1.5	30
17	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	3.2	10
18	Association of <i>Fusobacterium nucleatum</i> with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment. <i>Clinical Cancer Research</i> , 2021, 27, 2816-2826.	3.2	36

#	ARTICLE	IF	CITATIONS
19	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	3.2	62
20	Observed progression from melanosis with melanocyte hyperplasia to sinonasal melanoma with distant metastasis and a unique genetic rearrangement. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 948-953.	0.7	2
21	A rapid genotyping panel for detection of primary central nervous system lymphoma. <i>Blood</i> , 2021, 138, 382-386.	0.6	13
22	Odontoblast TRPC5 channels signal cold pain in teeth. <i>Science Advances</i> , 2021, 7, .	4.7	42
23	Do not sell regulatory science short. <i>Nature Medicine</i> , 2021, 27, 573-574.	15.2	2
24	National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020. <i>JCO Oncology Practice</i> , 2021, 17, e1763-e1773.	1.4	11
25	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. <i>Cancer Discovery</i> , 2021, 11, 1913-1922.	7.7	243
26	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
27	Development of a qualitative real-time RT-PCR assay for the detection of SARS-CoV-2: a guide and case study in setting up an emergency-use, laboratory-developed molecular microbiological assay. <i>Journal of Clinical Pathology</i> , 2021, 74, 496-503.	1.0	5
28	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Gene Fusion. <i>Oncologist</i> , 2021, 26, 818-824.	1.9	8
29	Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. <i>Cancers</i> , 2021, 13, 3572.	1.7	19
30	<i>MET</i> D1228N and D1246N are the Same Resistance Mutation in <i>MET</i> Exon 14 Skipping. <i>Oncologist</i> , 2021, 26, e2297-e2301.	1.9	3
31	Aneurysmal bone cyst with an unusual clinical presentation and a novel <i>VDR</i> - <i>USP6</i> fusion. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 833-836.	1.5	3
32	Two In Cis Variants—Two Worlds Apart. <i>Oncologist</i> , 2021, 26, 997-999.	1.9	0
33	Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study Indicate What Laboratory-Developed Test Regulation by the US Food and Drug Administration (FDA) Could Look Like. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1207-1217.	1.2	3
34	Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks. <i>Clinical Chemistry</i> , 2021, 68, 40-42.	1.5	11
35	Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 415-418.	1.2	10
36	Computed Tomography Imaging Features and Distribution of Metastases in <i>ROS1</i> -rearranged Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 153-159.e3.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Targeted Informatics for Optimal Detection, Characterization, and Quantification of FLT3 Internal Tandem Duplications Across Multiple Next-Generation Sequencing Platforms. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1162-1178.	1.2	20
38	Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. <i>EBioMedicine</i> , 2020, 57, 102860.	2.7	31
39	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	2.3	36
40	Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa040.	1.4	8
41	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. <i>Nature Biotechnology</i> , 2020, 38, 1174-1183.	9.4	251
42	Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. <i>FASEB Journal</i> , 2020, 34, 13877-13884.	0.2	117
43	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. <i>Journal of Infectious Diseases</i> , 2020, 222, 1955-1959.	1.9	72
44	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
45	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	3.2	12
46	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A, YAP1 and VIM-KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	2.9	24
47	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776.	0.5	68
48	Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000536.	3.9	17
49	Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 888-890.	0.5	2
50	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 1877-1885.	3.2	67
51	Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2020, 30, 1384-1389.	2.4	25
52	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
53	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	0.5	46
54	Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. <i>Nature Genetics</i> , 2020, 52, 692-700.	9.4	75

#	ARTICLE	IF	CITATIONS
55	Resistance to lorlatinib in <i>ROS1</i> fusion-positive non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, 9611-9611.	0.8	17
56	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2020, 38, e16686-e16686.	0.8	7
57	A Regulatory Science Initiative to Harmonize and Standardize Digital Pathology and Machine Learning Processes to Speed up Clinical Innovation to Patients. Journal of Pathology Informatics, 2020, 11, 22.	0.8	19
58	The validity of VALID act: Cost modeling cancer diagnostics regulation by the FDA.. Journal of Clinical Oncology, 2020, 38, e14124-e14124.	0.8	0
59	Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World Journal of Clinical Oncology, 2020, 11, 412-427.	0.9	4
60	BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES. Neuro-Oncology, 2020, 22, ii13-ii13.	0.6	0
61	Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Human Pathology, 2019, 83, 50-58.	1.1	70
62	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research, 2019, 25, 5561-5571.	3.2	64
63	Novel and established EWSR1 gene fusions and associations identified by next-generation sequencing and fluorescence in-situ hybridization. Human Pathology, 2019, 93, 65-73.	1.1	27
64	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. Clinical Cancer Research, 2019, 25, 6662-6670.	3.2	122
65	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
66	Clinical Validation of a Cell-Free DNA Gene Panel. Journal of Molecular Diagnostics, 2019, 21, 632-645.	1.2	15
67	Ultra-rapid drug delivery in the oral cavity using ultrasound. Journal of Controlled Release, 2019, 304, 1-6.	4.8	12
68	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	0.5	9
69	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics. Journal of Molecular Diagnostics, 2019, 21, 390-407.	1.2	15
70	Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist, 2019, 24, 1356-1367.	1.9	18
71	Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2019, 14, 816-824.	0.5	78
72	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	1.9	16

#	ARTICLE	IF	CITATIONS
73	Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. Immunotherapy, 2019, 11, 1193-1203.	1.0	3
74	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Journal of Thoracic Oncology, 2019, 14, e226-e228.	0.5	24
75	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. Cancers, 2019, 11, 2033.	1.7	26
76	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clinical Cancer Research, 2019, 25, 158-165.	3.2	81
77	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Human Pathology, 2019, 86, 1-11.	1.1	24
78	Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro-Oncology, 2019, 21, 596-605.	0.6	25
79	PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, e71-e74.	0.6	3
80	Frequency and feasibility of detecting FGFR mRNA expression in archival samples of patients with cholangiocarcinoma (CCA).. Journal of Clinical Oncology, 2019, 37, 281-281.	0.8	0
81	An artificial intelligence approach to variant calling of ALK resistance mutations.. Journal of Clinical Oncology, 2019, 37, 3079-3079.	0.8	0
82	Implementing Keytruda/Pembrolizumab Testing in Clinical Practice. Oncologist, 2018, 23, 647-649.	1.9	7
83	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	7.7	228
84	MET Amplification in Esophageal Squamous Carcinoma. International Journal of Surgical Pathology, 2018, 26, 731-732.	0.4	2
85	Food Addiction, High-Glycemic-Index Carbohydrates, and Obesity. Clinical Chemistry, 2018, 64, 64-71.	1.5	87
86	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	112
87	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	86
88	Artificial Intelligence Approach for Variant Reporting. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	1.0	13
89	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	17
90	Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma. Medicine (United States), 2018, 97, e13321.	0.4	8

#	ARTICLE	IF	CITATIONS
91	Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. <i>Scientific Reports</i> , 2018, 8, 16594.	1.6	11
92	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
93	The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. <i>American Journal of Pathology</i> , 2018, 188, 2839-2852.	1.9	51
94	Recent advances in the histological and molecular classification of endometrial stromal neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 665-678.	1.4	41
95	Genotype-targeted local therapy of glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8388-E8394.	3.3	40
96	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
97	Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9093-9093.	0.8	2
98	Implementing the DICOM Standard for Digital Pathology. <i>Journal of Pathology Informatics</i> , 2018, 9, 37.	0.8	93
99	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9045-9045.	0.8	0
100	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 872-877.	0.5	87
101	KIF13B-NRG1 Gene Fusion and KRAS Amplification in a Case of Natural Progression of Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2017, 25, 238-240.	0.4	9
102	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e155-e157.	0.5	9
103	Case 10-2017 "A 6-Month-Old Boy with Gastrointestinal Bleeding and Abdominal Pain. <i>New England Journal of Medicine</i> , 2017, 376, 1269-1277.	13.9	1
104	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
105	Silencer of Cytokine Signaling 1 gene is not hypermethylated in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 179, 158-160.	1.2	0
106	Origins of lymphatic and distant metastases in human colorectal cancer. <i>Science</i> , 2017, 357, 55-60.	6.0	358
107	Biopanel identifies expression status of targetable proteins in sinonasal melanoma. <i>Personalized Medicine</i> , 2016, 13, 291-301.	0.8	4
108	Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80



#	ARTICLE	IF	CITATIONS
109	A protein and mRNA expression-based classification of gastric cancer. <i>Modern Pathology</i> , 2016, 29, 772-784.	2.9	142
110	Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2016, 31, 973-982.	1.0	23
111	Health Care Infrastructure for Financially Sustainable Clinical Genomics. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 697-706.	1.2	15
112	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
113	Case 35-2016. <i>New England Journal of Medicine</i> , 2016, 375, 1983-1991.	13.9	2
114	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 1008-1016.	0.9	14
115	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2016, 11, e83-e85.	0.5	75
116	In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival. <i>European Spine Journal</i> , 2016, 25, 4016-4024.	1.0	28
117	HCP-12 IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT. <i>Neuro-Oncology</i> , 2015, 17, v103.4-v104.	0.6	0
118	Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. <i>Nature Communications</i> , 2015, 6, 7677.	5.8	90
119	Allelic Ratio of KRAS Mutations in Pancreatic Cancer. <i>Oncologist</i> , 2015, 20, e8-e9.	1.9	36
120	Classical pathology and mutational load of breast cancer - integration of two worlds. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 225-238.	1.3	91
121	Allelic ratio of KRAS mutations in pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4023.	0.8	32
122	Detecting predictive androgen receptor modifications in circulating prostate cancer cells. <i>Journal of Clinical Oncology</i> , 2015, 33, 5067-5067.	0.8	3
123	Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 29097-29110.	0.8	26
124	Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 4043-4043.	0.8	0
125	Osteoblast-Specific Krm2 Overexpression and Lrp5 Deficiency Have Different Effects on Fracture Healing in Mice. <i>PLoS ONE</i> , 2014, 9, e103250.	1.1	21
126	A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. <i>Modern Pathology</i> , 2014, 27, 524-534.	2.9	61



#	ARTICLE	IF	CITATIONS
127	H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO <sup>2</sup> â€“TRPA1â€“CGRP signalling pathway. <i>Nature Communications</i> , 2014, 5, 4381.	5.8	324
128	Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. <i>Oncotarget</i> , 2014, 5, 6404-6413.	0.8	82
129	AST/GOT1 expression status in primary resection specimen as a prognostic biomarker in human pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15245-e15245.	0.8	0
130	<i>SOCS1</i> Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Oncotarget</i> , 2013, 4, 35-47.	0.8	44
131	Absence Of BRAF and KRAS Hotspot Mutations In Primary Mediastinal and Other Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4325-4325.	0.6	0
132	Constitutively Active STAT6 Represses BCL6 in Primary Mediastinal B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2417-2417.	0.6	8
133	SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients. <i>Blood</i> , 2012, 120, 419-419.	0.6	0
134	Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18114-18119.	3.3	192
135	Ring Around the Roses. <i>International Journal of Surgical Pathology</i> , 2011, 19, 194-195.	0.4	0
136	<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib. <i>Journal of Clinical Oncology</i> , 2011, 29, 4803-4810.	0.8	404
137	Massive hepatomegaly and involvement by Janus kinase 2-positive myeloproliferative neoplasm. <i>Hepatology</i> , 2010, 52, 1855-1856.	3.6	0
138	Calcitonin receptorâ€“like receptor (CLR), receptor activityâ€“modifying protein 1 (RAMP1), and calcitonin geneâ€“related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. <i>Journal of Comparative Neurology</i> , 2008, 507, 1277-1299.	0.9	287
139	Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. <i>Journal of Comparative Neurology</i> , 2008, 507, spc1-spc1.	0.9	0
140	Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: Differences between peripheral and central CGRP receptor distribution. <i>Journal of Comparative Neurology</i> , 2008, 507, spc1-spc1.	0.9	0